

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucanabiomed.com W: www.nucanabiomed.com

NuCana to Present at BioTrinity on Wednesday 15th May 2013

NuCana BioMed ('NuCana'), a clinical stage biopharmaceutical company developing and commercialising exciting, new anti-cancer medicines, is pleased to announce that it will be presenting at BioTrinity 2013, the annual conference which showcases Europe's top life sciences companies.

BioTrinity 2013 is the third largest annual biopartnering meeting in Europe this year, a unique and powerful event for deal-making, attracting over 850 delegates from 30 countries including key investors and senior licensing executives from global pharma.

Hugh Griffith, CEO of NuCana commented: "I am looking forward to presenting an overview of our ProTide technology, which we believe will play an important part in shaping the future treatment of patients with cancer."

About NuCana BioMed

Headquartered in Edinburgh, UK, NuCana BioMed is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.